Efficacy and tolerability of exenatide twice daily and exenatide once weekly in Asian versus White patients with type 2 diabetes mellitus: A pooled analysis.

Sheu WH, Brunell SC, Blase E

Diabetes research and clinical practice9 Jan 2016Cited by 15 (Europe PMC)

PMID26827116DOI10.1016/j.diabres.2015.12.004PepBankPUB-26827116

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study17

17 results from studies that gave the peptide. 17 results from people.

01HumanObservational studyEfficacy outcome
In Asian and White patients with type 2 diabetes receiving either exenatide formulation, HbA1c decreased versus baseline.
In plain wordsHbA1c decreased from baseline in Asian and White patients receiving either exenatide formulation.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c change
Study
n = 4,625
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10μg exenatide BID or 2mg exenatide QW · 12-30 weeks (BID) or 24-30 weeks (QW)As given in this study (human).
Source sentences
Summary
At study end, glycated hemoglobin (HbA1c), fasting glucose (FG), body weight, post-prandial glucose (PPG), and PPG excursions were significantly reduced (all P<0.0001 vs baseline).
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of exenatide twice daily (BID) and once weekly (QW) were assessed in Asian versus White patients with type 2 diabetes mellitus (T2DM).
Summary · context
This post-hoc pooled analysis evaluated patients receiving 10μg exenatide BID for 12-30 weeks or 2mg exenatide QW for 24-30 weeks in exenatide clinical development program trials.
Report a problemFND-2682711601
02HumanObservational studyEfficacy outcome
In Asian and White patients with type 2 diabetes receiving either exenatide formulation, fasting glucose decreased versus baseline.
In plain wordsFasting glucose decreased from baseline in Asian and White patients receiving either exenatide formulation.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFasting glucose change
Study
n = 4,625
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10μg exenatide BID or 2mg exenatide QW · 12-30 weeks (BID) or 24-30 weeks (QW)As given in this study (human).
Source sentences
Summary
At study end, glycated hemoglobin (HbA1c), fasting glucose (FG), body weight, post-prandial glucose (PPG), and PPG excursions were significantly reduced (all P<0.0001 vs baseline).
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of exenatide twice daily (BID) and once weekly (QW) were assessed in Asian versus White patients with type 2 diabetes mellitus (T2DM).
Summary · context
This post-hoc pooled analysis evaluated patients receiving 10μg exenatide BID for 12-30 weeks or 2mg exenatide QW for 24-30 weeks in exenatide clinical development program trials.
Report a problemFND-2682711602
03HumanObservational studyEfficacy outcome
In Asian and White patients with type 2 diabetes receiving either exenatide formulation, body weight decreased versus baseline.
In plain wordsBody weight decreased from baseline in Asian and White patients receiving either exenatide formulation.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight change
Study
n = 4,625
Outcome group
Body weight · Metabolic and weight
Studied dose
10μg exenatide BID or 2mg exenatide QW · 12-30 weeks (BID) or 24-30 weeks (QW)As given in this study (human).
Source sentences
Summary
At study end, glycated hemoglobin (HbA1c), fasting glucose (FG), body weight, post-prandial glucose (PPG), and PPG excursions were significantly reduced (all P<0.0001 vs baseline).
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of exenatide twice daily (BID) and once weekly (QW) were assessed in Asian versus White patients with type 2 diabetes mellitus (T2DM).
Summary · context
This post-hoc pooled analysis evaluated patients receiving 10μg exenatide BID for 12-30 weeks or 2mg exenatide QW for 24-30 weeks in exenatide clinical development program trials.
Report a problemFND-2682711603
04HumanObservational studyEfficacy outcome
In Asian and White patients with type 2 diabetes receiving either exenatide formulation, post-prandial glucose decreased versus baseline.
In plain wordsPost-meal glucose decreased from baseline in Asian and White patients receiving either exenatide formulation.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePost-prandial glucose change
Study
n = 4,625
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10μg exenatide BID or 2mg exenatide QW · 12-30 weeks (BID) or 24-30 weeks (QW)As given in this study (human).
Source sentences
Summary
At study end, glycated hemoglobin (HbA1c), fasting glucose (FG), body weight, post-prandial glucose (PPG), and PPG excursions were significantly reduced (all P<0.0001 vs baseline).
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of exenatide twice daily (BID) and once weekly (QW) were assessed in Asian versus White patients with type 2 diabetes mellitus (T2DM).
Summary · context
This post-hoc pooled analysis evaluated patients receiving 10μg exenatide BID for 12-30 weeks or 2mg exenatide QW for 24-30 weeks in exenatide clinical development program trials.
Report a problemFND-2682711604
05HumanObservational studyEfficacy outcome
In Asian and White patients with type 2 diabetes receiving either exenatide formulation, post-prandial glucose excursions decreased versus baseline.
In plain wordsPost-meal glucose excursions decreased from baseline in Asian and White patients receiving either exenatide formulation.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePost-prandial glucose excursion change
Study
n = 4,625
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10μg exenatide BID or 2mg exenatide QW · 12-30 weeks (BID) or 24-30 weeks (QW)As given in this study (human).
Source sentences
Summary
At study end, glycated hemoglobin (HbA1c), fasting glucose (FG), body weight, post-prandial glucose (PPG), and PPG excursions were significantly reduced (all P<0.0001 vs baseline).
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of exenatide twice daily (BID) and once weekly (QW) were assessed in Asian versus White patients with type 2 diabetes mellitus (T2DM).
Summary · context
This post-hoc pooled analysis evaluated patients receiving 10μg exenatide BID for 12-30 weeks or 2mg exenatide QW for 24-30 weeks in exenatide clinical development program trials.
Report a problemFND-2682711605
06HumanObservational studyEfficacy outcome
In patients with type 2 diabetes, fasting glucose reductions did not differ by race for either exenatide formulation.
In plain wordsFasting glucose reductions did not differ between Asian and White patients for either exenatide formulation.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeFasting glucose response by race
Study
n = 4,625
Comparator
White patients
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10μg exenatide BID or 2mg exenatide QW · 12-30 weeks (BID) or 24-30 weeks (QW)As given in this study (human).
Source sentences
Summary
FG reduction did not differ by race for either exenatide formulation.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of exenatide twice daily (BID) and once weekly (QW) were assessed in Asian versus White patients with type 2 diabetes mellitus (T2DM).
Summary · context
This post-hoc pooled analysis evaluated patients receiving 10μg exenatide BID for 12-30 weeks or 2mg exenatide QW for 24-30 weeks in exenatide clinical development program trials.
Report a problemFND-2682711608
07HumanObservational studyEfficacy outcome
In patients with type 2 diabetes, Whites had greater weight reductions than Asians with either exenatide formulation.
In plain wordsWhite patients lost more weight than Asian patients with either exenatide formulation.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWeight response by race
Study
n = 4,625
Comparator
Asian patients
Outcome group
Body weight · Metabolic and weight
Studied dose
10μg exenatide BID or 2mg exenatide QW · 12-30 weeks (BID) or 24-30 weeks (QW)As given in this study (human).
Source sentences
Summary
Weight reduction was significantly greater in Whites (P<0.0001 vs Asians), regardless of exenatide formulation.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of exenatide twice daily (BID) and once weekly (QW) were assessed in Asian versus White patients with type 2 diabetes mellitus (T2DM).
Summary · context
This post-hoc pooled analysis evaluated patients receiving 10μg exenatide BID for 12-30 weeks or 2mg exenatide QW for 24-30 weeks in exenatide clinical development program trials.
Report a problemFND-2682711609
08HumanObservational studySafety outcome
In patients with type 2 diabetes receiving exenatide, nausea was a common adverse event.
In plain wordsNausea was a common side effect in patients receiving exenatide.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableNausea
Study
n = 4,625
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
10μg exenatide BID or 2mg exenatide QW · 12-30 weeks (BID) or 24-30 weeks (QW)As given in this study (human).
Source sentences
Summary
Common adverse events included nausea, headache, and diarrhea.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of exenatide twice daily (BID) and once weekly (QW) were assessed in Asian versus White patients with type 2 diabetes mellitus (T2DM).
Summary · context
This post-hoc pooled analysis evaluated patients receiving 10μg exenatide BID for 12-30 weeks or 2mg exenatide QW for 24-30 weeks in exenatide clinical development program trials.
Report a problemFND-2682711616
09HumanObservational studySafety outcome
In patients with type 2 diabetes receiving exenatide, headache was a common adverse event.
In plain wordsHeadache was a common side effect in patients receiving exenatide.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableHeadache
Study
n = 4,625
Outcome group
Adverse events · Nervous system and cognition
Studied dose
10μg exenatide BID or 2mg exenatide QW · 12-30 weeks (BID) or 24-30 weeks (QW)As given in this study (human).
Source sentences
Summary
Common adverse events included nausea, headache, and diarrhea.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of exenatide twice daily (BID) and once weekly (QW) were assessed in Asian versus White patients with type 2 diabetes mellitus (T2DM).
Summary · context
This post-hoc pooled analysis evaluated patients receiving 10μg exenatide BID for 12-30 weeks or 2mg exenatide QW for 24-30 weeks in exenatide clinical development program trials.
Report a problemFND-2682711617
10HumanObservational studySafety outcome
In patients with type 2 diabetes receiving exenatide, diarrhea was a common adverse event.
In plain wordsDiarrhea was a common side effect in patients receiving exenatide.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableDiarrhea
Study
n = 4,625
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
10μg exenatide BID or 2mg exenatide QW · 12-30 weeks (BID) or 24-30 weeks (QW)As given in this study (human).
Source sentences
Summary
Common adverse events included nausea, headache, and diarrhea.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of exenatide twice daily (BID) and once weekly (QW) were assessed in Asian versus White patients with type 2 diabetes mellitus (T2DM).
Summary · context
This post-hoc pooled analysis evaluated patients receiving 10μg exenatide BID for 12-30 weeks or 2mg exenatide QW for 24-30 weeks in exenatide clinical development program trials.
Report a problemFND-2682711618
11HumanObservational studyEfficacy outcome
In patients with type 2 diabetes receiving twice-daily exenatide, Asians had greater HbA1c reductions than Whites.
In plain wordsWith twice-daily exenatide, Asian patients had greater HbA1c reductions than White patients.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c response by race, twice daily
Study
n: not reported in source
Comparator
White patients
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10μg twice daily · 12-30 weeksAs given in this study (human).
Source sentences
Summary
For exenatide BID, HbA1c reduction was greater in Asians (P<0.0001 vs Whites), whereas HbA1c reduction did not differ by race for exenatide QW.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of exenatide twice daily (BID) and once weekly (QW) were assessed in Asian versus White patients with type 2 diabetes mellitus (T2DM).
Summary · context
This post-hoc pooled analysis evaluated patients receiving 10μg exenatide BID for 12-30 weeks or 2mg exenatide QW for 24-30 weeks in exenatide clinical development program trials.
Report a problemFND-2682711606
12HumanObservational studyEfficacy outcome
In patients with type 2 diabetes receiving weekly exenatide, HbA1c reductions did not differ by race.
In plain wordsWith weekly exenatide, HbA1c reductions did not differ between Asian and White patients.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeHbA1c response by race, weekly
Study
n: not reported in source
Comparator
White patients
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2mg once weekly · 24-30 weeksAs given in this study (human).
Source sentences
Summary
For exenatide BID, HbA1c reduction was greater in Asians (P<0.0001 vs Whites), whereas HbA1c reduction did not differ by race for exenatide QW.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of exenatide twice daily (BID) and once weekly (QW) were assessed in Asian versus White patients with type 2 diabetes mellitus (T2DM).
Summary · context
This post-hoc pooled analysis evaluated patients receiving 10μg exenatide BID for 12-30 weeks or 2mg exenatide QW for 24-30 weeks in exenatide clinical development program trials.
Report a problemFND-2682711607
13HumanObservational studyEfficacy outcome
In patients with type 2 diabetes receiving twice-daily exenatide, post-prandial glucose reductions were greater in Asians than Whites.
In plain wordsWith twice-daily exenatide, Asian patients had greater post-meal glucose reductions than White patients.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePost-prandial glucose response by race, twice daily
Study
n: not reported in source
Comparator
White patients
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10μg twice daily · 12-30 weeksAs given in this study (human).
Source sentences
Summary
PPG reduction was greater in Asians (P<0.0001 vs Whites) for exenatide BID but did not differ by race for exenatide QW.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of exenatide twice daily (BID) and once weekly (QW) were assessed in Asian versus White patients with type 2 diabetes mellitus (T2DM).
Summary · context
This post-hoc pooled analysis evaluated patients receiving 10μg exenatide BID for 12-30 weeks or 2mg exenatide QW for 24-30 weeks in exenatide clinical development program trials.
Report a problemFND-2682711610
14HumanObservational studyEfficacy outcome
In patients with type 2 diabetes receiving weekly exenatide, post-prandial glucose reductions did not differ by race.
In plain wordsWith weekly exenatide, post-meal glucose reductions did not differ between Asian and White patients.
Peptide
Exenatide (exendin-4)
Outcome
No significant changePost-prandial glucose response by race, weekly
Study
n: not reported in source
Comparator
White patients
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2mg once weekly · 24-30 weeksAs given in this study (human).
Source sentences
Summary
PPG reduction was greater in Asians (P<0.0001 vs Whites) for exenatide BID but did not differ by race for exenatide QW.
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of exenatide twice daily (BID) and once weekly (QW) were assessed in Asian versus White patients with type 2 diabetes mellitus (T2DM).
Summary · context
This post-hoc pooled analysis evaluated patients receiving 10μg exenatide BID for 12-30 weeks or 2mg exenatide QW for 24-30 weeks in exenatide clinical development program trials.
Report a problemFND-2682711611
15HumanObservational studyEfficacy outcome
In patients with type 2 diabetes receiving twice-daily exenatide, all-meal glucose excursion reductions were greater in Asians than Whites.
In plain wordsWith twice-daily exenatide, Asian patients had greater glucose excursion reductions across all meals than White patients.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseAll-meal glucose excursion response, twice daily
Study
n: not reported in source
Comparator
White patients
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10μg twice daily · 12-30 weeksAs given in this study (human).
Source sentences
Summary
For exenatide BID, reductions in PPG excursions for all meals were significantly greater in Asians (P<0.0001 vs Whites), whereas only post-breakfast and post-lunch excursions were significantly greater in Asians for exenatide QW (P=0.0009 and P=0.0189 vs Whites, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of exenatide twice daily (BID) and once weekly (QW) were assessed in Asian versus White patients with type 2 diabetes mellitus (T2DM).
Summary · context
This post-hoc pooled analysis evaluated patients receiving 10μg exenatide BID for 12-30 weeks or 2mg exenatide QW for 24-30 weeks in exenatide clinical development program trials.
Report a problemFND-2682711612
16HumanObservational studyEfficacy outcome
In patients with type 2 diabetes receiving weekly exenatide, post-breakfast glucose excursion reductions were greater in Asians than Whites.
In plain wordsWith weekly exenatide, Asian patients had greater post-breakfast glucose excursion reductions than White patients.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePost-breakfast glucose excursion response, weekly
Study
n: not reported in source
Comparator
White patients
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2mg once weekly · 24-30 weeksAs given in this study (human).
Source sentences
Summary
For exenatide BID, reductions in PPG excursions for all meals were significantly greater in Asians (P<0.0001 vs Whites), whereas only post-breakfast and post-lunch excursions were significantly greater in Asians for exenatide QW (P=0.0009 and P=0.0189 vs Whites, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of exenatide twice daily (BID) and once weekly (QW) were assessed in Asian versus White patients with type 2 diabetes mellitus (T2DM).
Summary · context
This post-hoc pooled analysis evaluated patients receiving 10μg exenatide BID for 12-30 weeks or 2mg exenatide QW for 24-30 weeks in exenatide clinical development program trials.
Report a problemFND-2682711613
17HumanObservational studyEfficacy outcome
In patients with type 2 diabetes receiving weekly exenatide, post-lunch glucose excursion reductions were greater in Asians than Whites.
In plain wordsWith weekly exenatide, Asian patients had greater post-lunch glucose excursion reductions than White patients.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePost-lunch glucose excursion response, weekly
Study
n: not reported in source
Comparator
White patients
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2mg once weekly · 24-30 weeksAs given in this study (human).
Source sentences
Summary
For exenatide BID, reductions in PPG excursions for all meals were significantly greater in Asians (P<0.0001 vs Whites), whereas only post-breakfast and post-lunch excursions were significantly greater in Asians for exenatide QW (P=0.0009 and P=0.0189 vs Whites, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of exenatide twice daily (BID) and once weekly (QW) were assessed in Asian versus White patients with type 2 diabetes mellitus (T2DM).
Summary · context
This post-hoc pooled analysis evaluated patients receiving 10μg exenatide BID for 12-30 weeks or 2mg exenatide QW for 24-30 weeks in exenatide clinical development program trials.
Report a problemFND-2682711614

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Efficacy and tolerability of exenatide twice daily and exenatide once weekly in Asian versus White patients with type 2 diabetes mellitus: A pooled analysis.

Summary

Results from this study17

Version history

Subjects

Publication types

MeSH terms

Keywords